Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib

Aim The identification of new prognostic factors able to stratify hepatocellular carcinoma patients candidate to first‐line therapy is urgent. In the present work we validated the prognostic value of the lenvatinib prognostic index. Methods Data of Eastern and Western patients treated with lenvatini...

Full description

Saved in:
Bibliographic Details
Published in:Hepatology research 2022-12, Vol.52 (12), p.1050-1059
Main Authors: Rimini, Margherita, Kang, Wonseok, Burgio, Valentina, Persano, Mara, Aoki, Tamoko, Shimose, Shigeo, Tada, Toshifumi, Kumada, Takashi, Sho, Takuya, Lai, Eleonora, Celsa, Ciro, Campani, Claudia, Tonnini, Matteo, Tamburini, Emiliano, Hiraoka, Atsushi, Takaguchi, Koichi, Nishida, Naoshi, Iwamoto, Hideki, Itobayashi, Ei, Tsuji, Kunihiko, Sakamoto, Naoya, Ishikawa, Toru, Toyoda, Hidenori, Kudo, Masatoshi, Kawaguchi, Takumi, Hatanaka, Takeshi, Nouso, Kazugiro, Suda, Goki, Cabibbo, Giuseppe, Marra, Fabio, Della Corte, Angelo, Ratti, Francesca, Pedica, Federica, Cobelli, Francesco, Aldrighetti, Luca, Scartozzi, Mario, Cascinu, Stefano, Casadei‐Gardini, Andrea
Format: Article
Language:English
Subjects:
Albumin
Bilirubin
Hepatocellular carcinoma
lenvatinib
Liver cancer
Medical prognosis
prognostic factors
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim The identification of new prognostic factors able to stratify hepatocellular carcinoma patients candidate to first‐line therapy is urgent. In the present work we validated the prognostic value of the lenvatinib prognostic index. Methods Data of Eastern and Western patients treated with lenvatinib as first‐line for Barcelona Clinic Liver Cancer stage B or C hepatocellular carcinoma were recollected. The lenvatinib prognostic index was composed by three classes of risk according with our previous study. The “low risk” group includes patients with prognostic nutritional index (PNI) >43.3 and with previous transarterial chemoembolization. The “medium risk” group includes patients with PNI >43.3, but without previous transarterial chemoembolization and patients with PNI
ISSN:1386-6346
1872-034X
DOI:10.1111/hepr.13824